1391979-18-2

Upstream product

• 1391979-14-8 2-methyl-5-trimethylsilanylethynyl-pyridin-3-ylamine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 914358-73-9 5-bromo-2-methylpyridin-3-ylamine 
• 911434-05-4 5-bromo-2-methyl-3-nitropyridine 
• 911434-04-3 2-(5-bromo-3-nitro-pyridin-2-yl)-malonic acid diethyl ester 
• 1211537-42-6 5-ethynyl-2-methyl-pyridin-3-ylamine 
• 98-09-9 benzenesulfonyl chloride 

Relevant academic research and scientific papers

5-Alkynyl-pyridines

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification

NEW 5-ALKYNYL-PYRIDINES

5-alkynyl-pyridine of general formula (I) which are inhibitors of the activity of PI3K alpha, and their use in the treatment of diseases characterized by excessive or abnormal cell proliferation, such as cancer.

NEW 5-ALKYNYL-PYRIDINES

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.

NEW 5-ALKYNYL-PYRIDINES

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of P13Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification.